Join

Enter Details

Comment on stories, receive email newsletters & alerts.

@
This is your permanent identity for Business Insider Australia
Your email must be valid for account activation
Minimum of 8 standard keyboard characters

Subscribe

Email newsletters but will contain a brief summary of our top stories and news alerts.

Forgotten Password

Enter Details


Back to log in

The CEO of a biotech startup with a $12 billion valuation explains why he didn't look to Silicon Valley for backing

Samumed CEOCNBC screenshotSamumed CEO Osman Kibar

Samumed is working on treatments to regenerate everything from hair to cartilage, which, if successful could be a huge medical breakthrough.

The startup has already reportedly reached a $12 billion valuation, much higher than most early-stage biotech companies. 

But it did this without turning to the usual crowd of investors in biotech startups — venture capital and private equity firms.

Instead, the company’s CEO, Osman Kibar, told CNBC that the funding came from “a number of family offices and sovereign funds and high net-worth individuals.”

When asked if the San Diego-based company had headed up north to seek funding from Silicon Valley investors, Kibar said they had not. Why avoid Silicon Valley, which has shown plenty of willingness to back early-stage biotech companies? Because he wants shareholders with a longer-term mindset, Kibar said. 

“So far, all our studies all our programs are making nice and steady progress,” he said. “But when it comes to investors, we have chosen not to go to the typical early-stage biotech investors — you know the VCs and the private equity funds — primarily because the timelines do not fit with our long-term goals.”

Samumed, which was founded in 2008, came out of stealth mode about half a year ago when it started presenting some of its data. The company’s technology targets certain proteins that scientists think play a critical role in the development and renewal of stem cells, the type of cells that give rise to other types of specialised cells, from eye cells to skin and hair cells.

One of Samumed’s farthest-along treatments in development is for baldness. The hope is that by using the treatment, people with androgenetic alopecia, a common form of hair loss, will be able to regrow some of their lost hair follicles, the layer of cells and connective tissue that envelope the root of a hair and are critical for its growth. Samumed most recently presented some phase 2 trial data on that treatment at the American Academy of Dermatology conference in March.

Watch the full interview:

 

NOW WATCH: Humans are defying the law of evolution

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.